

Chapter IV

#### Results

#### Effects of intravenous CaCl<sub>2</sub> infusion on general circulations

Group I : Control animals

As shown in table 1, the results are expressed on mean+S.E. After intravenous saline infusion, all parameters did not indicate the significant changes throughout the experimental period.

Group II : Hypercalcemic animals

Effects of intravenous CaCl<sub>2</sub> infusion on general circulations are shown in table 2. The CaCl<sub>2</sub> infusion caused a significant increase mean arterial blood pressure (MAP) from 109.45+9.21 to in 128.26+12.48 mmHg (p(0.01)) within 1 hour after CaCl<sub>2</sub> infusion and maintained at the higher level till the end of the experiment. Pulse packed cell volume (PCV) increased slightly pressure (PP) and throughout experimental period without statistically the significance. The significant decrease in heart rate(HR) from the control value of 145+10 to 105+19 beats/min (p(0.05)) was noted at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion. Cardiac output (CO) showed a marked decrease at the 3<sup>rd</sup> hour period of CaCl<sub>2</sub> infusion from 151.95+31.96 to 60.93+13.79 ml/min/kg.bw. (p(0.01). Plasma volume

# Table 1 Effects of intravenous isotonic saline infusion on general

circulations of four control dogs. (Mean+S.E.)

|                 | Saline infusion |     |        |               |             |
|-----------------|-----------------|-----|--------|---------------|-------------|
|                 | 1               |     | Sal    | ine infusion  |             |
| Variables       | control         |     | 1 hr.  | 2 hr.         | 3 hr.       |
| MAP             | 126.63          |     | 128.10 | 128.16        | 129.97      |
| (mmHg)          | <u>+</u> 7.67   | 1.1 | +8.25  | +8.66         | +7.36       |
| РР              | 38.75           |     | 35.62  | 34.58         | 35.62       |
| (mmHg)          | +4.27           |     | +2.57  | +2.08         | +2.57       |
| HR              | 146             |     | 144    | 141           | 143         |
| (beats/min)     | <u>+</u> 9      |     | +8     | <u>+</u> 10   | <u>+</u> 10 |
| со              | 160.75          |     | 164.23 | 150.82        | 140.69      |
| (ml/min/kg.bw.) | <u>+</u> 19.94  |     | +17.84 | +25.37        | +13.09      |
| PV .            | 49.49           |     | 47.38  | 47.41         | 48.39       |
| (ml/kg.bw.)     | +4.16           |     | +3.70  | +3.57         | +4.05       |
| BV              | 66.14           |     | 62.77  | 62.81         | 64.12       |
| (ml/kg.bw.)     | +5.24           |     | +4.89  | +4.81         | +5.39       |
| PCV             | 25.25           |     | 25.00  | 25.00         | 25.00       |
| (%)             | <u>+</u> 0.63   |     | +0.41  | +0.41         | +0.41       |
| TPR             | 100             |     | 98.86  | 110.56        | 116.89      |
| (%)             |                 | 1   | +3.96  | <u>+</u> 7.05 | +6.21       |
|                 |                 |     |        |               |             |

.

25

4

.

|                 |               | Saline inf           | usion        |        |  |  |  |
|-----------------|---------------|----------------------|--------------|--------|--|--|--|
|                 |               | After CaCl, infusion |              |        |  |  |  |
| Variables       | Control       | 1 hr.                | 2 hr.        | 3 hr.  |  |  |  |
|                 |               | *                    | *            | **     |  |  |  |
| MAP             | 109.45        | 128.26               | 136.20       | 144.39 |  |  |  |
| (mmHg)          | +9.21         | +12.48               | +12.35       | +8.96  |  |  |  |
| РР              | 41.00         | 43.94                | 45.52        | 51.81  |  |  |  |
| (mmHg)          | +2.32         | +4.44                | +4.44        | +9.83  |  |  |  |
|                 |               |                      | *            | *      |  |  |  |
| HR              | 145           | 117                  | 105          | 105    |  |  |  |
| (beats/min)     | <u>+</u> 10   | +23                  | <u>+</u> 19  | +19    |  |  |  |
|                 |               |                      | **           | **     |  |  |  |
| СО              | 151.95        | 107.05               | 72.78        | 60.93  |  |  |  |
| (mi/min/kg.bw.) | +31.96        | +22.81               | +19.50       | +13.79 |  |  |  |
|                 |               | *                    | *            | *      |  |  |  |
| PV              | 46.20         | 39.81                | 31.08        | 29.17  |  |  |  |
| (ml/kg.bw.)     | +4.28         | +3.72                | +3.03        | +1.07  |  |  |  |
|                 |               | *                    | *            | *      |  |  |  |
| BV              | 66.81         | 57.32                | 45.40        | 42.92  |  |  |  |
| (ml/kg.bw.)     | +6.01         | +5.59                | +4.95        | +2.71  |  |  |  |
| PCV             | 30.80         | 30.40                | 31.10        | 31.80  |  |  |  |
| ( % )           | <u>+</u> 1.60 | <u>+</u> 1.48        | <u>+1.42</u> | +1.31  |  |  |  |
|                 |               | *                    | **           | ***    |  |  |  |
| TPR             | 100           | 182.05               | 273.73       | 338.99 |  |  |  |
| (%)             |               | +29.62               | +22.03       | +21.39 |  |  |  |
|                 |               |                      |              |        |  |  |  |

Table 2 Effects of intravenous CaCl<sub>2</sub> infusion on general circulations of five dogs. (Mean+S.E.)

p-value with respect to control, \*p<0.05, \*\* p<0.01, \*\*\* p<0.001

(PV) as well as blood volume(BV) decreased from  $46.20\pm4.28$  to 29.17±1.07 ml/kg.bw. (p(0.05) and from  $66.81\pm6.01$  to  $42.92\pm2.71$  ml/kg.bw. (p(0.05) at the end of the experiment. Total peripheral vascular resistance (TPR) increased sharply to 182 % at the 1<sup>st</sup> hour period and significant increased progressively to 273 % and 338 % at the 2<sup>nd</sup> and 3<sup>rd</sup> hour period of CaCl<sub>2</sub> infusion, respectively.

# <u>Group III</u> : Animals pretreated with a low dose of Verapamil (6 µg/kg in the rate of 1 ml/min)

The results of changes in general circulations in dogs given intravenous CaCl<sub>2</sub> infusion and pretreated with a low dose of Verapamil are shown in table 3. During given Verapamil alone, mean arterial blood pressure decreased significantly from the control value of 110.34+8.15 to 91.24+5.36 mmHg (p(0.05) and then it was not altered significantly from the control value after 3 hour period of intravenous CaCl<sub>2</sub> infusion. Pulse pressure increased slightly only at the 1<sup>st</sup> hour period of CaCl<sub>2</sub> infusion from 39.98+4.96 to 46.82+5.21 mmHg(p<0.05). Heart rate significantly decreased in the period of infusion Verapamil alone  $(p\langle 0.05)$  and more significantly decreased after 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion from 145+5 to 98+4 beats/min (p(0.01) at the end of the experiment. A significant decline in cardiac output was apparent from 99.78+8.08 to 53.96+10.42 ml/min/kg.bw. (p<0.05) after CaCl<sub>2</sub> infusion. At the  $3^{rd}$  hour period after CaCl<sub>2</sub> infusion, both plasma volume blood volume marked decreased from 42.81+1.96 to 23.77+1.88 ml/kg.bw. and from 63.66+3.18 to 35.09+1.84 ml/kg.bw. (p<0.001), respectively.

Table 3 Effects of intravenous CaCl<sub>2</sub> infusion on general circulations of five dogs pretreated with a low dose of Verapamil (6 µg/kg in the rate of 1 ml/min). (Mean+S.E.)

à.

|                 |               | Verapamil infusion                |                               |                                |                       |  |
|-----------------|---------------|-----------------------------------|-------------------------------|--------------------------------|-----------------------|--|
|                 |               | Before CaCl, After CaCl, infusion |                               |                                |                       |  |
| Variables       | Control       | infusion                          | 1 hr.                         | 2 hr.                          | 3 hr.                 |  |
|                 |               | *                                 |                               |                                |                       |  |
| МАР             | 110.34        | 91.24                             | 109.08                        | 110.73                         | 111.43                |  |
| (mmHg)          | +8.15         | +5.36                             | +5.22                         | +7.17                          | +9.82                 |  |
|                 |               |                                   | *                             |                                |                       |  |
| PP              | 39.98         | 40.88                             | 46.82                         | 45.75                          | 46.05                 |  |
| (mmHg)          | +4.96         | +4.90                             | +5.21                         | +6.07                          | +5.62                 |  |
|                 |               | *                                 | *                             | **                             | **                    |  |
| HR              | 145           | 129                               | 108                           | 101                            | 98                    |  |
| (beats/min)     | +5            | <u>+</u> 7                        | +6                            | <u>+</u> 7                     | +4                    |  |
|                 |               |                                   | **                            | ***                            | **                    |  |
| со              | 99.78         | 97.24                             | 64.88                         | 45.25                          | 53.96                 |  |
| (ml/min/kg.bw.) | +8.08         | <u>+</u> 8.06                     | +6.17                         | +6.89                          | +10.42                |  |
| 4               |               |                                   | **                            | ***                            | ***                   |  |
| PV              | 42.81         | 37.04                             | 30.44                         | 21.42                          | 23.77                 |  |
| (ml/kg.bw.)     | <u>+</u> 1.96 | +2.78                             | <u>+</u> 1.31                 | <u>+</u> 1.73                  | +1.88                 |  |
|                 |               |                                   | **                            | **                             | ***                   |  |
| BV              | 63.66         | 56.09                             | 44.41                         | 31.43                          | 35.09                 |  |
| (ml/kg.bw.)     | +3.18         | +5.62                             | <u>+</u> 1.06                 | +2.02                          | +1.84                 |  |
| PCV             | 32.60         | 33.40                             | 31.55                         | 32.05                          | 32.60                 |  |
| (%)             | +1.66         | +1.44                             | +1.75                         | +2.01                          | +2.06                 |  |
|                 | 1             | **                                | **                            | **                             | *                     |  |
| TPR             | 100           | 79.85                             | 142.58                        | 226.24                         | 198.25                |  |
| (%)             |               | <u>+</u> 3.00                     | +8.41                         | +22.94                         | +25.88                |  |
| TPR<br>(%)      | 100           | **<br>79.85<br><u>+</u> 3.00      | **<br>142.58<br><u>+</u> 8.41 | **<br>226.24<br><u>+</u> 22.94 | *<br>198.25<br>+25.88 |  |

p-value with respect to control, p<0.05, \*\* p<0.01, \*\*\* p<0.001

28

.

Total peripheral vascular resistance decreased about 20 % from the control level in the period of infusion Verapamil alone and then it increased gradually to 142 %, 226 % and 198 % at the  $1^{st}$ ,  $2^{nd}$  and  $3^{rd}$  hour period during CaCl<sub>2</sub> infusion, respectively. During experiment no change in packed cell volume was noted.

#### <u>Group IV</u> : Animals pretreated with a high dose of verapamil (12 µg/kg in the rate of 1 ml/min)

Results of changes in general circulations in dogs given intravenous CaCl<sub>2</sub> infusion and pretreated with the high dose of Verapamil are shown in table 4. During given a high dose of Verapamil alone, mean arterial blood pressure decreased markedly from the control value of 115.98+4.96 to 88.28+4.32 mmHg (p(0.001) and then it returned to normal values after 3 hour period of CaCl<sub>2</sub> infusion. Pulse pressure increased slightly at the 1<sup>st</sup> hour of CaCl<sub>2</sub> infusion from 39.50+6.04 to 50.17+6.98 mmHg (p(0.05). A significant decline in heart rate was observed at the 1<sup>st</sup> hour of CaCl<sub>2</sub> infusion from 145+9 to 113+14 beats/min (p<0.05) and declined progressively to 108+26 beats/min  $(p\langle 0.01)$  at the end of the experiment. Cardiac output increased significantly in the period of pretreated with Verapamil alone (p(0.01))but it returned to a lower level as compared to the control value from 132.71+24.99 to 91.31+24.21 and to 80.64+16.41 ml/min/kg.bw. (p<0.01) at the  $2^{nd}$  and  $3^{rd}$  hour period of CaCl<sub>2</sub> infusion, respectively. It was found that plasma volume decreased gradually from 46.02+3.59 to 36.45+4.90 (p(0.01) and to 37.43+3.34 ml/kg.bw. (p(0.05) at the 2<sup>nd</sup> and

Table 4 Effect of intravenous CaCl<sub>2</sub> infusion on general circulations of five dogs pretreated with a high dose of Verapamil (12 µg/kg in the rate of 1 ml/min ). (Mean+S.E. )

|                |            |              | Verapami      | l infusior | 1      |
|----------------|------------|--------------|---------------|------------|--------|
|                |            | Before CaCl, | After         | CaCl, inf  | Iusion |
| Variables      | Control    | infusion     | . 1 hr.       | 2 hr.      | 3 hr.  |
|                |            | ***          |               |            |        |
| MAP            | 115.98     | 88.28        | 113.18        | 115.47     | 119.15 |
| (mmHg)         | +4.96      | +4.32        | <u>+</u> 7.98 | +6.58      | +7.74  |
|                |            |              | *             |            |        |
| PP             | 39.50      | 41.50        | 50.17         | 46.25      | 46.75  |
| (mmHg)         | +6.04      | +4.23        | +6.98         | +6.68      | +7.19  |
|                |            |              | *             | **         | **     |
| HR             | 145        | 134          | 113           | 106        | 108    |
| (beats/min)    | <u>+</u> 9 | <u>+</u> 13  | +14           | +15        | +26    |
|                |            | **           |               | * *        | **     |
| со             | 132.71     | 184.10       | 120.43        | 91.31      | 80.64  |
| (ml/min/kg.bw. | ) +24.99   | +26.66       | +30.52        | +24.21     | +16.41 |
|                |            |              |               | **         | *      |
| PV             | 46.02      | 48.62        | 43.12         | 36.45      | 37.43  |
| (ml/kg.bw.)    | +3.59      | +2.99        | +4.58         | +4.90      | +3.34  |
|                |            | *            |               | **         |        |
| BV             | 66.72      | 71.27        | 62.46         | 53.29      | 56.04  |
| (ml/kg.bw.)    | +4.59      | +3.89        | +5.73         | +5.36      | +3.18  |
| PCV            | 31.00      | 31.70        | 31.10         | 32.50      | 33.40  |
| (%)            | +2.89      | +2.89        | +2.81         | +3.39      | +3.67  |
|                |            | **           |               | **         | **     |
| TPR            | 100        | 54.21        | 113.64        | 155.25     | 169.54 |
| (%)            | - *        | +4.88        | +10.39        | +12.25     | +3.84  |

P-value with respect to control, p<0.05, \*\* p<0.01, \*\*\* p<0.001

 $3^{rd}$  hour of CaCl<sub>2</sub> infusion, whereas blood volume increased in the period of infusion Verapamil alone (p40.05), and then it decreased from the control value of 66.72+4.59 to 53.29+5.36 ml/kg.bw. (p(0.01)) at the  $2^{nd}$  hour of CaCl<sub>2</sub> infusion. Total peripheral vascular resistance decreased promptly near 46% from the control value in animals infusion with Verapamil alone and then it increased significantly to 155 % and 169 % at the  $2^{nd}$  and  $3^{rd}$  hour after CaCl<sub>2</sub> infusion. During the experiment, no change in packed cell volume was observed.

# <u>Group V</u> : Animals pretreated with Prazosin (20 µg/kg in the rate of 1 ml/min)

The results of changes in general circulations in dogs given intravenous CaCl<sub>2</sub> infusion and pretreated with Prazosin are shown in table 5. Mean arterial blood pressure decreased significantly from the control value of 116.12+5.08 to 95.81+3.94 mmHg (p(0.01) during given and then it was not altered from the control value Prazosin alone after 3 hour period of CaCl<sub>2</sub> infusion. Pulse pressure decreased from 38.00+0.93 to 29.26+1.78 mmHg( $p\langle 0.05$ ) and heart rate also decreased gradually from 153+11 to 110+10 beats/min (p(0.05) at the end of the experiment. A marked decline in cardiac output was observed in the 2<sup>na</sup> and  $3^{rd}$  hour period of CaCl<sub>2</sub> infusion from 179.72+14.34 to 101.97+1.87 and to 99.65+5.23 m1/min/kg bw. (p(0.01) respectively. Plasma volume showed a slight decrease at the 1 st hour period from 48.36+0.84 to 44.25+1.37 and decreased progressively to 37.00+2.20 ml/kg.bw. (p(0.01)) at the end of the experiment. whereas blood volume decreased

|                 |               |                | Prazosin    | infusion    |          |
|-----------------|---------------|----------------|-------------|-------------|----------|
|                 |               | Before CaCl    | Af          | ter CaCl    | infusion |
| Variables       | Control       | infusion       | 1 hr.       | 2 hr.       | 3 hr.    |
|                 |               | **             |             |             |          |
| MAP             | 116.12        | 95.81          | 113.81      | 118.96      | 116.22   |
| (mmHg)          | +5.08         | +3.94          | +4.20       | +6.84       | +6.47    |
|                 |               | ***            | *           | *           | *        |
| PP              | 38.00         | 27.00          | 28.99       | 30.25       | 29.26    |
| (mmHg)          | +0.93         | +1.22          | +1.27       | +1.95       | +1.78    |
|                 |               | *              | *           | *           | *        |
| HR              | 153           | 137            | 106         | 106         | 110      |
| (beats/min)     | <u>+</u> 11   | <u>+</u> 12    | <u>+</u> 12 | <u>+</u> 10 | +10      |
|                 |               |                |             | **          | **       |
| со              | 179.72        | 188.93         | 134.93      | 101.97      | 99.65    |
| (ml/min/kg.bw.) | +14.34        | <u>+</u> 11.60 | +12.64      | +1.87       | +5.23    |
|                 |               |                | *           | **          | **       |
| PV ·            | 48.36         | 48.84          | 44.25       | 38.21       | 37.00    |
| (ml/kg.bw.)     | +0.84         | +0.25          | +1.37       | +2.85       | +2.20    |
|                 |               |                |             | **          | **       |
| BV              | 71.72         | 70.88          | 64.89       | 55.38       | 53.70    |
| (ml/kg.bw.)     | <u>+</u> 1.59 | +2.20          | +2.00       | +3.19       | +2.16    |
| PCV             | 32.00         | 31.80          | 31.15       | 31.10       | 31.25    |
| (%)             | +2.07         | +2.15          | +2.38       | +2.34       | +2.34    |
|                 |               | **             |             | **          | *        |
| TPR             | 100           | 72.48          | 129.40      | 179.05      | 182.47   |
| (%)             |               | +4.35          | +15.00      | +11.14      | +18.76   |

Table 5 Effects of intravenous CaCl<sub>2</sub> infusion on general circulations of five dogs pretreated with Prazosin (20 µg/kg in the rate of 1 ml/min). (Mean+S.E.)

.

p-value with respect to control, p<0.05, p<0.01, p<0.001

persistently from 71.27+1.59 to 55.38+3 19 and to 53.70+2 16 ml/kg.bw.  $(p\langle 0.01 \rangle)$  at the 2<sup>nd</sup> and 3<sup>rd</sup> hour after CaCl<sub>2</sub> infusion, respectively. During given Prazosin alone, total peripheral vascular resistance decreased about 28 % from the control value and then it increased significantly to 179 % and 182 % at the 2<sup>nd</sup> and 3<sup>rd</sup> hour period after CaCl<sub>2</sub> infusion. No change in packed cell volume was observed during experiment.

# <u>Group VI</u> : Animals pretreated with the combination of high dose of Verapamil and Prazosin

The results are summarized in table 6. During given the combined drugs period, mean arterial blood pressure decreased markedly from 114.62+3.31 to 79.96+2.84 mmHg (p(0.001) and maintained at the significant lower level till the end of the experiment. It was found that pulse pressure, cardiac output and packed cell volume did not significant change during the experiment. Heart rate decreased from 143+6 to 109+10 beats/min (p(0.05) at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion. Not only plasma volume but also blood volume decreased significantly from 49.71+3.34 to 43.12+3.36 m1/kg.bw. (p(0.05) and from 71.24+5.15 to 67.47+6.29 ml/kg.bw. (p(0.05) at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion, respectively. During given the combined drugs period, total peripheral vascular resistance decreased by approximately 43 % from the control value and it returned to the control value after 3 hour period of CaCl<sub>2</sub> infusion.

N 163

33

| Table 6 | Effects of intravenous CaCl infusion on general circulations |
|---------|--|
|         | of five dogs pretreated with the combination of high dose of |
|         | Verapamil and Prazosin. ( Mean+S.E. )                        |

|                    |               | Verapamil + Prazosin infusion |               |               |               |   |
|--------------------|---------------|-------------------------------|---------------|---------------|---------------|---|
|                    |               | Before CaCl <sub>2</sub>      | Aft           | er CaCl, in   | fusion        |   |
| Variables          | Control       | infusion                      | 1 hr.         | 2 hr.         | 3 hr.         |   |
|                    |               | ***                           | ***           | **            | **            |   |
| MAP                | 114.62        | 79.96                         | 97.64         | 98.64         | 99.66         |   |
| (mmHg)             | +3.31         | <u>+</u> 2.84                 | +3.88         | +2.49         | <u>+</u> 1.85 |   |
| PP                 | 35.00         | 36.00                         | 35.00         | 35.00         | 35.00         |   |
| (mmHg)             | <u>+</u> 1.58 | <u>+</u> 3.32                 | <u>+</u> 2.73 | <u>+</u> 3.53 | <u>+</u> 5.18 |   |
|                    |               |                               | **            | *             | *             |   |
| HR                 | 143           | 133                           | 117           | 112           | 109           |   |
| (beats/min)        | <u>+</u> 6    | <u>+</u> 4                    | +6            | <u>+</u> 9    | <u>+</u> 10   |   |
| СО                 | 176.58        | 221.22                        | 175.34        | 161.23        | 139.53        |   |
| (ml/min/kg.bw.)    | +4.42         | +18.82                        | +28.28        | +31.12        | +0.46         |   |
|                    |               |                               |               |               | *             |   |
| PV                 | 49.71         | 48.32                         | 43.99         | 44.71         | 43.12         |   |
| (ml/kg.bw.)        | +3.34         | +2.32                         | +4.04         | +2.25         | +3.36         |   |
|                    |               |                               |               |               | *             |   |
| BV                 | 71.24         | 68.98                         | 62.48         | 63.34         | 67.47         |   |
| (ml/kg.bw.)        | +5.15         | +4.40                         | +6.47         | +4.31         | +6.29         |   |
| PCV                | 29.60         | 29.40                         | 29.00         | 28.80         | 29.00         | - |
| ( <sup>9</sup> 0 ) | <u>+</u> 3.14 | <u>+</u> 3.18                 | <u>+</u> 2.96 | +3.31         | <u>+</u> 3.27 |   |
|                    |               | **                            |               |               |               |   |
| TPR                | 100           | 57.79                         | 93.95         | 110.29        | 130.22        |   |
| (%)                |               | +6.36                         | +12.99        | +21.77        | +24.05        |   |
|                    |               |                               |               |               |               |   |

P-value with respect to control, p<0.05, \*\* p<0.01, \*\*\* p<0.001



In comparison, the effects of intravenous CaCl<sub>2</sub> infusion on general circulations showed an increase in mean arterial blood pressure in group II-VI (Fig.1). Animals pretreatment with neither Verapamil nor Prazosin (group II) produced a sharp increase in mean arterial blood pressure. On the other hand, animals in group III-V could maintain the mean arterial blood pressure to the control level when received  $CaCl_2$  infusion. Furthermore, in group VI, mean arterial blood pressure was lower significantly as compared to the control group throughout the experimental period. It should be noted that pulse pressure increased from the control value of animals in group II-IV, whereas group V decreased significantly (Fig.2). Heart rate (Fig.2), plasma volume and blood volume (Fig.3) of group II-VI progressive decreased significantly in the same pattern after CaCl<sub>2</sub> infusion. There was a statistically significant decrease in cardiac output of group II-V (Fig.4) during the experimental period. Total peripheral vascular resistance of group II-V showed a gradual increase after CaCl<sub>2</sub> infusion (Fig.5). No change in packed cell volume was observed during the experiment of all groups. However, it was noted that pulse pressure, cardiac output and total peripheral vascular resistance of group VI did not significantly alter from the control value throughout the experimental period.



Fig.1:Percentage changes of mean arterial blood pressure(MAP) in dcgs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose cf Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dcse of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S.E.

p-values with respect to control condition of each group, p<0.05,
\*\*p<0.01, \*\*\* p<0.001</pre>

p-values with respect to group I at the same time interval,  $\frac{\partial \mathcal{C} \mathcal{Q}}{p < 0.001}$ 



Fig.2:Changes of pulse pressure(PP) and heart rate(HR) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+ Pra.]. The values are mean+S.E. p-values with respect to control condition of each group, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001</pre>

p-values with respect to groupI at the same time interval,  $p^{0} < 0.05$ ,  $p^{0} < 0.01$ ,  $p^{0} < 0.001$ 

37



Fig.3 :Percentage changes of plasma volume(PV) and blood volume(BV)in dcgs infusion with CaCl<sub>2</sub>and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose cf Verapamil and Prazosin[Ver.(H)+Pra.].The values are mean+S.E. p-values with respect to control condition of each group, p<0.05, \*\*p<0.01, \*\*\*p<0.001</pre>

p-values with respect to groupI at the same time interval, p<0.05, p<0.01, p<0.001



Fig.4:Percentage changes of cardiac output(CO) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil (Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.]

The values are mean+S.E.

p-values with respect to control condition of each group,  $*^{*}p<0.01$ ,  $*^{**}p<0.001$ 

p-values with respect to groupI at the same time interval, p<0.01,  $Q^{QQ}_{p} > 0.001$ 



Fig.5:Percentage changes of total peripheral resistance(TPR) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose cf Verapamil and Frazosin[Ver.(H)+Pra.]

The values are mean+S.E.

p-values with respect to control condition of each group, p<0.05, p<0.01

p-values with respect to groupI at the same time interval, p<0.05, p<0.01, p<0.001

Effects of intravenous CaCl<sub>2</sub> infusion on renal hemodynamics

#### Group I : Control animals

The results are shown in table 7. There were significant increases in the rate of urine flow (V), urinary osmolar excretion  $(U_{OSM}V)$  and osmolar clearance  $(C_{OSM})$  by approximately 49 %, 18% and 19 % respectively at the 3<sup>rd</sup> hour after intravenous isotonic saline infusion; whereas urinary osmolality decreased from 825.88+115.36 to 628.91+91.41 mOsm/kg (p $\langle 0.05 \rangle$ ) at the end of the experiment. No significant differance in the other variables were noted.

#### Group II : Hypercalcemic animals

Results in table 8 show that effective renal plasma flow (ERPF) and effective renal blood flow (ERBF) decreased significantly from 7.11+1.08 to 3.99+0.32 ml/min/kg.bw. (p(0.05) and from 10.41+1.75 to 5.83+0.54 ml/min/kg.bw. (p<0.05) within 2 hour after CaCl<sub>2</sub> infusion and were decreased progressively to 3.79+0.36 and to 5.60+0.59 ml/min/kg.bw. (p<0.05), respectively at the end of the experiment. It has been shown that the similar trend was observed for rate (GFR) from 1.81+0.17 to glomerular filtration 1.42+0.14 ml/min/kg.bw. (p < 0.05). There was a marked increase in renal vascular resistance (RVR) by approximately 175  $\%~(p\zeta 0.05)$  at the 1  $^{st}$  hour of  ${\rm CaCl}_2$  infusion and more significant to 243 % (p(0.01) at the end of the experiment. No significant change in renal fraction (RF) was

|                             |                |               | Saline        | infusion      |               | _ |
|-----------------------------|----------------|---------------|---------------|---------------|---------------|---|
|                             |                | 111           |               | Saline infus  | ion           | , |
| Variables                   |                | Control       | 1 hr.         | 2 hr.         | 3 hr.         | _ |
| ERPF<br>(ml/mi              | n/ka.bw.)      | 7.11          | 6:92<br>+0.59 | 6.56<br>+0.44 | 6.91<br>+0.48 | - |
| 0.000                       |                | -             | _             | -             |               |   |
| ĒRBF                        |                | 9.49          | 9.17          | 8.89          | 9.16          |   |
| (ml/mi                      | n/kg.bw.)      | +0.60         | +0.81         | +0.62         | +0.67         |   |
| GFR                         |                | 1.72          | 1.73          | 1.69          | 1.78          |   |
| (ml/mi                      | n/kg.bw.)      | +0.10         | +0.10         | +0.10         | +0.08         |   |
| FF (%)                      |                | 24.26         | 25 - 21       | 25.31         | 25.98         |   |
| •                           |                | <u>+</u> 1.34 | +1.31         | +1.08         | +1.32         |   |
| RF (%)                      |                | 6.27          | 6.05          | 6.28          | 6.75          |   |
|                             |                | +0.88         | +0.75         | +0.88         | +0.73         |   |
| RVR (%                      | )              | 100           | 105.31        | 108.20        | 106.70        |   |
|                             |                |               | +4.09         | +4.24         | +2.73         |   |
| v (ml                       | /min)          | 0.37          | 0.42          | 0.42          | 0.55          |   |
|                             |                | +0.08         | +0.10         | +0.08         | +0.09         |   |
| UV                          | (Osm/min)رosm/ | 271.49        | 279.87        | 280.31        | 319.88        |   |
| USI                         | - 70           | +39.74        | +34.33        | +32.36        | +34.38        |   |
| C_                          | (ml/min)       | 0.95          | 0.97          | 0.97          | 1.13          |   |
| Osm                         | ÷              | +0.14         | +0.12         | +0.11         | +0.11         |   |
| c <sub>u</sub>              | (ml/min)       | -0.58         | -0.55         | -0.54         | -0.57         |   |
| <sup>n</sup> 2 <sup>0</sup> |                | +0.07         | +0.04         | +0.05         | +0.08         |   |
| P                           | (mOsm/kg)      | 285.50        | 285.87        | 285.00        | 281.63        |   |
| OSIN                        |                | +1.65         | +0.97         | +3.30         | +3.22         |   |
| P                           | (mEq/L)        | 136.75        | 135.00        | 135.75        | 135.50        |   |
| Na                          | -              | +1.60         | <u>+</u> 1.51 | +0.69         | +1.69         |   |
| P                           | (mEq/L)        | 3.12          | 3.22          | 3.18          | 3.20          |   |
| Г                           |                | +0.06         | +0.06         | +0.04         | +0.06         |   |
| P <sub>C</sub>              | (mEq/L)        | 115.25        | 114.75        | 114.87        | 115.50        |   |
| CT                          | -              | +1.56         | +0.98         | +1.26         | +1.73         |   |
| P                           | (mEq∕L)        | 3.26          | 3_26          | 3_22          | 3.12          |   |
| Cā                          | -              | +0.05         | +0.07         | +0.03         | +0.07         |   |
| P                           | (mEq/L)        | 2 .81         | 2.86          | 2 - 84        | 2.89          |   |
| Pi                          | •*             | +0.35         | +0.37         | +0.36         | +0.39         |   |

Table 7 Effects of intravenous isotonic saline infusion on renal hemodynamics in the left kidney of four control dogs. (Mean+S.E.)

P-value with respect to control, \*p<0.05

|                             | Saline infusion |        |                     |               |  |  |
|-----------------------------|-----------------|--------|---------------------|---------------|--|--|
|                             |                 |        | After CaCl infusion |               |  |  |
| Variables                   | Control         | 1 hr.  | 2 hr.               | 3 hr.         |  |  |
| ERPF                        | 7,11            | 4.76   | 3.99                | 3.79          |  |  |
| (ml/min/kg.bw.)             | <u>+1.08</u>    | +0.47  | +0.32               | +0.36         |  |  |
| ERBF                        | 10.41           | 6.89   | 5.83                | 5.60          |  |  |
| (ml/min/kg.bw.)             | +1.75           | +0.76  | +0.54               | +0.59         |  |  |
| GFR                         | 1.81            | 1.59   | 1.36                | 1.42          |  |  |
| (ml/min/kg.bw.)             | +0.17           | +0.18  | +0.14               | +0.14         |  |  |
| FF (%)                      | 27.22           | 33.52  | 34.48               | 37.74         |  |  |
|                             | +3.24           | +1.84  | +2.61               | +1.86         |  |  |
| RF (%)                      | 8.24            | 8.32   | 10.13               | 11.05         |  |  |
|                             | +1.97           | +2.29  | +2.11               | +2.10         |  |  |
| RVR (%)                     | 100             | 175.36 | 220.22              | 243.35        |  |  |
|                             |                 | +22.68 | +32.53              | +24.18        |  |  |
| V (ml/min)                  | 0.32            | 0.83   | 0.84                | 1.03          |  |  |
|                             | +0.13           | +0.17  | +0.15               | <u>+</u> 0.12 |  |  |
| UV (uOsm/min)               | 188.42          | 344.79 | 343.29              | 304.20        |  |  |
| Osm 👎                       | +41.35          | +58.21 | +47.59              | +28.10        |  |  |
| Corr (ml/min)               | 0.66            | 1.21   | 1.21                | 0.97          |  |  |
| Cem                         | +0.14           | +0.20  | +0.17               | +0.13         |  |  |
| C <sub>LO</sub> (ml/min)    | -0.39           | -0.38  | -0.33               | 0.66          |  |  |
| <sup>1</sup> 2 <sup>0</sup> | +0.04           | +0.08  | +0.08               | +0.02         |  |  |
| P (mOsm/kg)                 | 283.80          | 279.50 | 281.80              | 283.00        |  |  |
| OSM                         | +1.28           | +2.63  | <u>+</u> 1.06       | +1.06         |  |  |
| P (mEq/L)                   | 138.60          | 138,40 | 138.40              | 139.20        |  |  |
| Na                          | +1.36           | +2.06  | <u>+</u> 2.13       | +1.48         |  |  |
| P <sub>v</sub> (mEq/L)      | 3.22            | 3.36   | 3.45                | 3.37          |  |  |
| ×                           | +0.12           | +0.12  | +0.25               | +0.24         |  |  |
| P (mFq/L)                   | 111.80          | 114.40 | 115.30              | 116.30        |  |  |
|                             | <u>+</u> 1.93   | +2.55  | <u>+</u> 2.19       | +2.04         |  |  |
| P(mEq/L)                    | 3.82            | 6.28   | 6***                | 6.87          |  |  |
| Ca -                        | +0.09           | +0.16  | +0.14               | +0.17         |  |  |
| P <sub>Di</sub> (mEq/L)     | 2.67            | 3.31   | 3. 65               | 3.88          |  |  |
| <b>F1</b>                   | +0.22           | +0.17  | +0.37               | +0.40         |  |  |

Table 8 Effects of intravenous CaCl<sub>2</sub> infusion on renal hemodynamics in the left kidney of five dogs. (Mean+S.E.)

P-value with respect to control, p<0.05, p<0.01, p<0.001

•.

.

.

observed; whereas filtration fraction (FF) increased from 27.22+3.24 to 37.74+1.86 % (p(0.05) at the  $3^{rd}$  hour of CaCl<sub>2</sub> infusion. The rate of urine flow (V) increased progressively from the control value of 0.32+0.13 to 1.03+0.12 ml/min (p(0.01) while urine osmolality ( $U_{Osm}$ ) decreased from 950.00+234.78 to 350.60+37.81 mOsm/kg (p 0.05) at the end of the CaCl\_2 infusion. Both urinary osmolar excretion ( $\rm U_{Osm}V)$  and osmolar clearance ( $C_{Osm}$ ) increased significantly from 188.42+41.35 to 304.20+28.10 JOSm/min (p(0.01) and from 0.66+0.14 to 0.97+0.13 ml/min (p(0.05) at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion, respectively. Free water clearance ( $C_{H_0O}$ ) increased significantly from -0.39+0.04 to 0.66+0.02 ml/min (p(0.05) at the end of CaCl<sub>2</sub> infusion. Plasma osmolality ( $P_{Osm}$ ), plasma concentration of sodium ( $P_{Na}$ ), potassium ( $P_K$ ) and chloride ( $P_{C1}$ ) were constant throughout the experiment; while plasma concentration of calcium ( $P_{Ca}$ ) increased gradually from 3.82+0.09 to 6.28+0.16 mEq/L (p(0.001) at the 1<sup>st</sup> hour and to 6.87+0.17 mEq/L (p(0.001) at the  $3^{rd}$  hour of CaCl<sub>2</sub> infusion. The plasma concentration of inorganic phosphorus ( $P_{p_i}$ ) was also enchanced during CaCl<sub>2</sub> infusion (p(0.01).

# <u>Group III</u> : Animals pretreated with a low dose of Verapamil (6 ug/kg in the rate of 1 ml/min)

The result of changes in renal hemodynamics in dogs given intravenous  $CaCl_2$  infusion and combined pretreatment of low dose of Verapamil are shown in table 9. After  $CaCl_2$  infusion, effective renal plasma flow and effective renal blood flow decreased progressively from the control value of 7.33+1.34 to 5.24+1.22 ml/min/kg.bw. (p(0.01)

and from 10.80+1.82 to 7.67+1.65 ml/min/kg.bw. (p(0.001) at the end of the experiment; whereas glomerular filtration rate decreased significantly only at the  $3^{rd}$  hour of CaCl<sub>2</sub> infusion from 1.47+0.16 to 1.25+0.11 ml/min/kg.bw. (p<0.05). It was found filtration that fraction and renal fraction increased significantly about 30 % and 57% respectively at the 2<sup>nd</sup> hour of CaCl<sub>2</sub> infusion. During given Verapamil alone, renal vascular resistance reduced gradually about 15% from the control value and then it increased to 127 % at the 1<sup>st</sup> hour of CaCl<sub>2</sub> infusion and maintained the higher level to 154 % at the end of the experiment. The urine osmolality reduced from 632.10+83.77 to 253.20+12.95 mOsm/kg (p(0.05) at the  $3^{rd}$  hour of CaCl<sub>2</sub> infusion. Not only the rate of urine flow but also urinary osmolar excretion increased progressively from 0.34+0.08 to 1.68+0.16 m1/min (p(0.001) and from 190.84+27.14 to 419.63+35.26 uOsm/min (p(0.01), respectively at the end of the experiment. Osmolar clearance increased persistently and showed a significant value at the  $2^{nd}$  hour (p(0.05) and the  $3^{rd}$ hour of  $CaCl_2$  infusion (p(0.01). Similar increase in free water clearance was also exhibited significantly in all periods of CaCl<sub>2</sub> infusion. No significant differances of plasma osmolality, plasma concentration of sodium, potassium and chloride were noted between before and after  $CaCl_2$  infusion. Plasma concentration of calcium was significant increased continuously all the periods of experiment (p**(**0.001). Plasma concentration of inorganic phosphorus was also increased persistently (p(0.01) throughout the experiment.

|                            |               | Verapamil infusion         |                 |                                  |                          |
|----------------------------|---------------|----------------------------|-----------------|----------------------------------|--------------------------|
|                            |               | . Before CaCl <sub>2</sub> |                 | After CaCl <sub>2</sub> infusion |                          |
| Variables                  | Control       | infusion                   | 1 hr.           | 2 hr.                            | 3 hr.                    |
| ERPF                       | 7.33          | 7.04                       | · 5.87          | 5.09                             | 5.24                     |
| (ml/min/kg.bw.)            | <u>+</u> 1.34 | <u>+</u> 1.09              | +1.13           | <u>+</u> 1.03                    | +1.22                    |
| ERBF                       | 10.80         | 10.51                      | 8.53            | 7.43                             | 7.67                     |
| (ml/min/kg.bw.)            | <u>+</u> 1.82 | <u>+</u> 1.49              | <u>+</u> 1.55   | <u>+</u> 1.38                    | +1.65                    |
| GFR                        | 1.47          | 1.48                       | 1.38            | 1.28                             | 1.25                     |
| (ml/min/kg.bw.)            | +0.16         | +0.16                      | <u>+</u> 0.12   | +0.10                            | +0.11                    |
| FF (%)                     | 21.05         | 21.74                      | 25.44           | 27.77                            | 27.59                    |
|                            | <u>+</u> 1.61 | <u>+</u> 1.57              | +2.89           | +3.42                            | +3.92                    |
| RF (%)                     | 10.64         | 10.75                      | 12.85           | 16.22                            | 14.02                    |
|                            | +1.14         | +0.77                      | +1.45           | +1.28                            | +0.75                    |
| RVR (%)                    | 100           | 85.75<br>+3.42             | 127.23<br>+7.05 | 156.25<br><u>+</u> 15.52         | 154.95<br><u>+</u> 18.67 |
| V (ml/min)                 | 0.34          | 0.43                       | 0.92            | 1.43                             | 1.68                     |
|                            | +0.08         | <u>+</u> 0.06              | +0.25           | +0.21                            | +0.16                    |
| U V (USsm/min)             | 190.84        | 190.15                     | 331.20          | 381.75                           | 419.63                   |
| Osm                        | +27.14        | <u>+</u> 9.40              | <u>+</u> 67.14  | +62.56                           | +35.26                   |
| C <sub>Osm</sub> (ml/min)  | 0.66          | 0.66                       | 1.14            | 1.32                             | 1.46                     |
|                            | +0.09         | <u>+</u> 0.02              | <u>+</u> 0.22   | +0.21                            | +0.11                    |
| C <sub>H2</sub> O (ml/min) | -0.32         | -0.21                      | -0.23           | 0.11                             | 0.23                     |
|                            | +0.03         | +0.04                      | +0.07           | +0.06                            | +0.07                    |
| P (mOsm/kg)                | 288.40        | 286.00                     | 287.90          | 286.90                           | 285.10                   |
| Osm                        | +2.64         | <u>+</u> 3.20              | +2.26           | +3.08                            | <u>+</u> 4.18            |
| P (mEq/L)                  | 143.60        | 143.60                     | 143.30          | 143.80                           | 143.00                   |
| Na                         | <u>+</u> 1.12 | <u>+</u> 1.25              | <u>+</u> 0.81   | <u>+</u> 0.51                    | +0.91                    |
| P <sub>K</sub> (mEq/L)     | 3.00          | 2.89                       | · 3.08          | 3.10                             | 3.08                     |
|                            | <u>+</u> 0.08 | <u>+</u> 0.09              | +0.05           | <u>+</u> 0.05                    | +0.06                    |
| P (mEq/L)                  | 114.20        | 111.80                     | 113.70          | 114.90                           | 115.30                   |
|                            | <u>+</u> 1.23 | <u>+</u> 0.80              | <u>+</u> 1.46   | <u>+</u> 1.25                    | <u>+</u> 1.36            |
| P (mEq/L)                  | 3.67          | 3.67                       | 6 <u>*</u> 17   | 6.40                             | 6.60                     |
| Ca                         | +0.23         | +0.26                      | +0.18           | +0.22                            | +0.27                    |
| P (mEq/L)                  | 2.58          | 2.61                       | 3.37            | 3.68                             | 3.79                     |
| Pi                         | +0.18         | +0.20                      | +0.27           | +0.23                            | +0.28                    |

Table 9 Effects of intravenous CaCl<sub>2</sub> infusion on renal hemodynamics in the left kidney of five dogs pretreated with a low dose of Verapamil (6 µg/kg in the rate of 1 ml/min). (Mean+S.E.)

P-value with respect to control, p<0.05, \*\*p<0.01, \*\*\*p<0.001



<u>Group IV</u> : Animals pretreated with a high dose of Verapamil ( 12 µg/kg in the rate of 1 ml/min )

The results show in the table 10 Intravenous CaCl<sub>2</sub> infusion caused a decline of both effective renal plasma flow and effective renal blood flow from the control value of 6.49+0.57 to 4.50+0.29 ml/min/kg.bw. (p(0.05) and from 9.42+0.75 to 6.75+0.23 ml/min/kg.bw.  $(p \langle 0.05 \rangle)$  at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion. During given Verapamil alone, glomerular filtration rate increased slightly and then reduced to a lower level as compared to the control value at the end of the experiment (p(0.05)). Renal fraction did not alter, whereas filtration fraction increased continuously throughout the end of CaCl<sub>2</sub> (p(0.01)). Verapamil infusion alone caused a decline of infusion renal vascular resistance approximately 32 % (p (0.001)) but after combined infusion with CaCl<sub>2</sub> solution, it was increased and reached to be a statistical significance (p(0.05) to 122 %, 134 % and 144 % at the  $1^{st}$  ,  $2^{nd}$  and  $3^{rd}$  hour of CaCl<sub>2</sub> infusion, respectively. The rate of urine flow increased (p(0.05)) while urine osmolality was reduced persistently (p(0.01)) after CaCl<sub>2</sub> infusion. Urinary osmolar excretion and osmolar clearance constant increased and revealed a significant value at the 2<sup>nd</sup> and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion. Free water clearance increased significantly in all the experimental periods during CaCl<sub>2</sub> infusion. However, it was shown that plasma osmolality, plasma concentration of sodium, potassium and chloride were not significant differance between before and after CaCl<sub>2</sub> infusion. Either plasma concentration of calcium or inorganic phosphorus was increased markedly

|                            |               | Verapamil infusion |                         |                          |                      |
|----------------------------|---------------|--------------------|-------------------------|--------------------------|----------------------|
|                            |               | Before CaCl        | 2. Aft                  | ter CaCl <sub>2</sub>    | infusion             |
| Variables                  | Control       | infusion           | 1 hr.                   | 2 hr.                    | 3 hr.                |
| ERPF                       | 6.49          | 7.10               | 5.09                    | 4_68                     | 4.50                 |
| (ml/min/kg.bw.)            | <u>+</u> 0.57 | <u>+</u> 0.38      | +0.22                   | +0.30                    | <u>+</u> 0.29        |
| ERBF                       | 9.42          | 10.44              | 7.45                    | 6.94                     | 6.75                 |
| (ml/min/kg.bw.)            | +0.75         | +0.56              | +0.52                   | +0.23                    | <u>+</u> 0.23        |
| GFR                        | 1.41          | 1.56               | 1.32                    | 1.31                     | 1.23                 |
| (ml/min/kg.bw.)            | <u>+</u> 0.07 | +0.03              | +0.05                   | +0.05                    | <u>+</u> 0.08        |
| FF (%)                     | 22.08         | 22.13              | 26.07                   | 28.34                    | 27.82                |
|                            | <u>+</u> 1.24 | <u>+</u> 1.05      | +0.79                   | +1.66                    | +2.52                |
| RF (%)                     | 8.57          | 6.22               | .7.81                   | 9.99                     | 9.81                 |
|                            | <u>+</u> 2.10 | +1.02              | +1.69                   | +2.31                    | <u>+</u> 1.88        |
| RVR (%)                    | 100           | 68.29<br>+2.87     | 122.40<br><u>+</u> 6.55 | 134.63<br><u>+</u> 10.03 | 144.22<br>+15.44     |
| V (ml/min)                 | 0.25          | 0.58               | 1.44                    | 1:81                     | 1.65                 |
|                            | +0.06         | +0.20              | +0.48                   | +0.48                    | +0.36                |
| U V (USm/min)              | 172.93        | 235.71             | 448.68                  | 432.92                   | .375.51              |
| Osm                        | +21.97        | +50.58             | +126.56                 | +104.50                  | <u>+</u> 68.56       |
| C (ml/min) .               | 0.61          | 0.85               | 1.60                    | 1.52                     | 1.32                 |
| Osm                        | +0.07         | <u>+</u> 0.17      | +0.45                   | +0.36                    | +0.24                |
| C <sub>H2</sub> O (ml/min) | -0_26         | -0.27              | -0.16                   | 0.27                     | 0.53                 |
|                            | +0.04         | +0.05              | +0.07                   | +0.19                    | +0.25                |
| P (mOsm/kg)                | 283.20        | 271.80             | 281.50                  | 282.00                   | 282 <sup>-</sup> .50 |
| Osm                        | <u>+</u> 1.76 | <u>+</u> 10.18     | <u>+</u> 1.98           | <u>+</u> 1.48            | <u>+</u> 1.41        |
| P (mEq/L)                  | 140.80        | 140.20             | 140.80                  | 141.60                   | 141.20               |
| Na                         | <u>+</u> 0.37 | <u>+</u> 0.19      | +0.34                   | <u>+</u> 0.19            | <u>+</u> 0.75        |
| P (mEq/L)                  | 3.26          | 3.20               | 3.20                    | 3.15                     | 3.27                 |
| K                          | +0.10         | +0.10              | +0.08                   | <u>+</u> 0.11            | +0.09                |
| P (mEq/L)                  | 117.60        | 117.00             | 117.60                  | 119.30                   | 118.40               |
|                            | <u>+</u> 0.92 | <u>+</u> 0.89      | <u>+</u> 0.51           | <u>+</u> 0.51            | <u>+</u> 0.76        |
| P (mEq/L)                  | 3.71          | 3.69               | 6.40                    | 6.69                     | 6.81                 |
| Ca                         | +0.08         | +0.10              | +0.20                   | +0.32                    | <u>+</u> 0.34        |
| P <sub>Pi</sub> (mEq/L)    | 2.54          | 2.53               | 3.22                    | 3_51                     | 3.45                 |
|                            | +0.12         | +0.14              | +0.08                   | <u>+</u> 0.05            | +0.13                |

Table 10 Effects of intravenous CaCl<sub>2</sub> infusion on renal hemodynamics in the left kidney of five dogs pretreated with a high dose of Verapamil (12 µg/kg in the rate of 1 ml/min). (Mean+S.E.)

P-value with respect to control, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001

from  $3.71\pm0.08$  to  $6.81\pm0.34$  mEq/L (p(0.01) and from  $2.54\pm0.12$  to  $3.45\pm0.13$  mEq/L at the end of CaCl<sub>2</sub> infusion, respectively.

#### Group V : Animals pretreated with Prazosin

( 20 µg/kg in the rate of 1 ml/min )

As shown in table 11. Both effective renal plasma flow and effective renal blood flow were declined continuously from the control value an achieved significant value at the 2<sup>nd</sup> and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion (p(0.05). CaCl<sub>2</sub> infusion caused a reduction of glomerular filtration rate at all experimental periods (p < 0.01). Owing to the fall in glomerular filtration rate and effective renal plasma flow, the filtration fraction did not alter significantly (Fig.11). No alteration of renal fraction was also observed. During given Prazosin alone, renal vascular resistance reduced markedly about 21 % and then it returned to a higher level after  $CaCl_2$  infusion by approximately 144 % and 152 % at the 2<sup>nd</sup> and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion, respectively. The rate of urine flow increased progressively while urine osmolality reduced significantly (p(0.05)) all the experimental periods of CaCl<sub>2</sub> infusion. At the same time period, urinary osmolar excretion as well as osmolar clearance elevated significantly (p(0.05)). Free water clearance increased persistently and revealed a statistical significance at the and  $3^{rd}$  hour of CaCl<sub>2</sub> infusion (p<0.001, p<0.01). There were no 2<sup>nd</sup> alterations in plasma osmolality, plasma concentrations of sodium, potassium and chloride throughout the experimental period of CaCl<sub>2</sub> infusion. Plasma concentration of calcium increased strikingly and

|                            |                | Prazosi                  | n infusio        | n                        |                  |
|----------------------------|----------------|--------------------------|------------------|--------------------------|------------------|
|                            | <b>-</b> .     | Before CaCl <sub>2</sub> | After C          | aCl <sub>2</sub> infu    | sion             |
| Variables                  | Control        | infusion                 | 1 hr.            | 2 hr.                    | 3 hr.            |
| ERPF                       | 5.85           | 6.06                     | 4.81             | 4.30                     | 4.04             |
| (ml/min/kg.bw.)            | +0.69          | +0.66                    | +0.40            | +0.57                    | +0.61            |
| ERBF                       | 8.59           | 8.90                     | 7.01             | 6.33                     | 5.95             |
| (ml/min/kg.bw.)            | <u>+</u> 1.00  | +0.94                    | +0.67            | +0.99                    | <u>+</u> 1.01    |
| GFR                        | 1.44           | 1.50                     | 1.28             | 1.29                     | 1.23             |
| (ml/min/kg.bw.)            | <u>+</u> 0.11  | <u>+</u> 0.11            | +0.09            | +0.08                    | +0.09            |
| FF (%)                     | 24.52          | 25.36                    | 27.01            | 31.19                    | 32.04            |
|                            | <u>+</u> 1.51  | <u>+</u> 1.47            | +1.50            | +2.41                    | +2.67            |
| RF (%)                     | 4.76           | 4.69                     | 5.58             | 6.45                     | 6.31             |
|                            | +0.35          | +0.42                    | +1.05            | <u>+</u> 1.20            | +1.50            |
| RVR (%)                    | 100            | 79,90<br>+2.85           | 121.35<br>+12.30 | 144.17<br><u>+</u> 13.67 | 152.23<br>+16.58 |
| V (ml/min)                 | 0.23           | 0.40                     | 0.80             | 1.10                     | 1.30             |
|                            | +0.05          | +0.09                    | +0.19            | +0.26                    | +0.36            |
| U_V (μOsm/min)             | 151.31         | 210.58                   | 300.95           | 314.93                   | 338.81           |
| Osm                        | <u>+</u> 14.21 | +28.81                   | +44.88           | +50.25                   | +55.58           |
| C (ml/min)                 | 0.52           | 0.72                     | 1.03             | 1.08                     | 1.16             |
| Osm                        | +0.05          | <u>+</u> 0.09            | +0.15            | +0.16                    | +0.18            |
| C <sub>H2</sub> O (ml/min) | -0.28          | -0.32                    | -0.20            | 0.09                     | 0.23             |
|                            | +0.04          | <u>+</u> 0.08            | +0.08            | +0.07                    | +0.16            |
| P (mOsm/kg)                | 290.60         | 288.20                   | 288.90           | 288.80                   | 289.70           |
| Osm                        | +3.03          | +3.64                    | +2.45            | +2.36                    | +2.94            |
| P (mEq/L)                  | 138.60         | 139.40                   | 138.90           | 138.60                   | 137.60           |
| Na                         | <u>+</u> 1.21  | <u>+</u> 1.53            | <u>+</u> 1.04    | <u>+</u> 1.23            | +0.88            |
| P (mEq/L)                  | 3.24           | 3.26                     | 3,24             | 3.16                     | 3.19             |
| K                          | +0.05          | <u>+</u> 0.05            | +0.07            | +0.06                    | +0.09            |
| P <sub>C1</sub> (mEq/L)    | 119.60         | 116.80                   | 119.30           | 119.10                   | 119.20           |
|                            | <u>+</u> 0.87  | <u>+</u> 1.15            | <u>+</u> 0.81    | <u>+</u> 0.24            | <u>+</u> 0.79    |
| P (mEq/L)                  | 3.47           | 3.52                     | 5.91             | 6.12                     | 6.36             |
| Ca                         | +0.07          | +0.06                    | +0.17            | +0.22                    | +0.26            |
| P (mEq/L)                  | 2_44           | 2.81                     | 3.47             | 3.54                     | 3.47             |
|                            | +0_17          | +0.10                    | +0.13            | +0.09                    | +0.13            |

Table 11 Effects of intravenous CaCl<sub>2</sub> infusion on renal hemodynamics in the left kidney of five dogs pretreated with Prazosin

( 20 ير 20/kg in the rate of 1 ml/min). (Mean+S.E.)

P-value with respect to control, p<0.05, \*\*p<0.01, \*\*\*p<0.001

plasma concentration of inorganic phosphorus also increased slightly from  $3.47\pm0.07$  to  $6.36\pm0.26$  mEq/L (p(0.001) and from  $2.44\pm0.17$  to  $3.47\pm0.13$  mEq/L (p(0.05), respectively at the end of the experiment.

# <u>Group VI</u> : Animals pretreated with the combination both of the high dose of Verapamil and Prazosin

The results are shown in the table 12. It was noted that effective renal plasma flow, effective renal blood flow, filtration fraction and renal fraction were not affected by intravenous CaCl, infusion throughout the experimental period in dogs pretreated with the combined drugs of high dose of Verapamil and Prazosin. Glomerular filtration rate trened to be a higher level and reached significantly only at the 1<sup>st</sup> hour of CaCl<sub>2</sub> infusion from 1.52+0.09 to 1.79+0.02 ml/min/kg.bw. (p(0.05). Renal Vascular resistance showed a marked reduction (p(0.001)) in all the periods of CaCl<sub>2</sub> infusion. The rate of urine flow increased from 0.28+0.05 to 1.78+0.38 ml/min (p(0.05) at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion. Urine osmolality declined progressively (p(0.01) during CaCl<sub>2</sub> infusion. Either urinary osmolar excretion or free water clearance gradually increased from214.37+23.25 to 362.57+67.29 uOsm/min (p(0.05) and from 0.49+0.07 to 0.47+0.13 m1/min (p(0.01) respectively at the end of the experiment. The significant increased in osmolar clearance was observed at the  $1^{st}$  hour (p(0.01) and the  $2^{nd}$  hour (p(0.05) but insignificant change was apparent at the hour of CaCl<sub>2</sub> infusion. No marked changes of plasma osmolality. 3<sup>rd</sup> plasma concentration of sodium potassium and chloride were apparent in

51

|                          |               | Verapam       | il and Pra           | zosin in      | fusion        |
|--------------------------|---------------|---------------|----------------------|---------------|---------------|
| ÷.                       |               | Before GaCl,  | After CaCl, infusion |               |               |
| Variables                | Control       | infusion      | 1 hr.                | · 2 hr.       | 3 hr.         |
| ERPF                     | 6.35          | 7.35          | 6.89                 | 6.71          | 6.89          |
| (ml/min/kg.bw.)          | +0.54         | +0.98         | +0.66                | +0.62         | +0.76         |
| ERBF                     | 9.00          | 10.32         | 9.58                 | 9.36          | 9.63          |
| (ml/min/kg.bw.)          | +0.59         | <u>+</u> 1.05 | +0.67                | +0.57         | +0.81         |
| GFR                      | 1.52          | 1.70          | 1.79                 | 1.69          | 1.68          |
| (ml/min/kg.bw.)          | +0.09         | +0.16         | +0.02                | +0.08         | +0.82         |
| FF (%)                   | 24.40         | 23.81         | 26.88                | 25.86         | 25.17         |
|                          | +2.19         | +2.09         | +2.20                | +2.11         | +2.19         |
| RF (%)                   | 5.09          | 4.73          | 5.87                 | 6,61          | 7.95          |
|                          | +0.24         | <u>+</u> 0.42 | +0.69                | <u>+</u> 1.19 | <u>+</u> 1.33 |
| RVR (%)                  | 100           | 62.21         | 80.34                | 82.91         | 82.56         |
|                          |               | +4.30         | +1.73                | +1.97         | +5.07         |
| V (ml/min)               | 0.28          | 0.42          | 1.54                 | 1.89          | 1.78          |
|                          | +0.05         | +0.11         | +0.25                | +0.36         | <u>+</u> 0.33 |
| UV (µOsm/min)            | 214.37        | 247.84        | 471.32               | 450.38        | 362.57        |
| USIII -                  | +23.25        | +30.32        | +48.37               | +83.72        | +67.29        |
| Cosm (ml/min)            | 0.77          | 0.88          | 1.69                 | 1.61          | 1.31          |
| - Sau                    | <u>+</u> 0.08 | <u>+0.11</u>  | +0.17                | +0.30         | +0.24         |
| C <sub>HO</sub> (ml/min) | -0.49         | -0.45         | -0.15                | 0.29          | 0.47          |
|                          | +0.07         | +0.06         | +0.09                | +0.10         | +0.13         |
| P (mOsm/kg)              | 279.20        | - 282.00      | 278.50               | 278.90        | 275.90        |
| Cent Inc.                | +4.25         | +1.58         | +2.19                | +3.16         | <u>+</u> 1.70 |
| P <sub>Na</sub> (mFq/L)  | 146.60        | 145.60        | 145.90               | 145.10        | 143.80        |
| na                       | +1.56         | <u>+1.43</u>  | +1.51                | +1.52         | +1.31         |
| P <sub>v</sub> (mEq/L)   | . 3.14        | 3.18          | 3.33                 | 3.57          | 3.51          |
| K -                      | +0.06         | +0.05         | +0.04                | +0.19         | +0.18         |
| (mEq/L)                  | 120.60        | 118.00        | 118.50               | 117.70        | 117.50        |
|                          | +1.80         | +0.71         | +0.76                | +0.95         | +0.96         |
| <sup>2</sup> (mEq/L)     | 3 .51         | 3 54          | 5 2 5 1              | 6***          | 6,18          |
| ca ·                     | +0.05         | +0,06         | +0.06                | +0.22         | +0.08         |
| P. (mEq/L)               | 2,77          | 2_81          | 3.05                 | 3.46          | 3,29          |
| P1 ***                   | +0.32         | +0.33         | +0.26                | +0.22         | +0.20         |

Table 12 Effects of intravenous CaCl<sub>2</sub> infusion on renal hemodynamics in the left kidney of five dogs pretreated with the combination of the high dose of Verapamil and Prazosin. (Mean+S.E.)

P-value with respect to control, p<0.05, p<0.01, \*\*\* p<0.001,

animals between pre and post  $CaCl_2$  infusion. The prominent increase in plasma concentration of calcium was observed from  $3.51\pm0.05$  to  $6.18\pm0.08$  mEq/L (p $\langle 0.001 \rangle$ ) while plasma concentration of inorganic phosphorus elevated slightly from  $2.77\pm0.32$  to  $3.29\pm0.20$ mEq/L (p $\langle 0.05 \rangle$ ) at the end of the experiment.

In comparison, the effect of intravenous  $CaCl_2$  infusion on renal hemodynamics showed a significant decrease in effective renal plasma flow (Fig.6), effective renal blood flow (Fig.7) and glomerular filtration rate (Fig.8) in animals of group II-V. Animals without pretreatment of Verapamil or Prazosin (group II) produced a striking reduction in effective renal plasma flow, effective renal blood flow glomerular filtration rate when compared with the animals in and group III-V after CaCl<sub>2</sub> infusion. It was indicated that these variables could be elevated to a higher level in animals pretreatment with a combined doses of Verapamil and Prazosin (group VI). The similar opposite pattern was also observed in renal vascular resistance Animals in group II-VI showed a higher level of renal (Fig.9). fraction when compared with the control group (group I), whereas filtration fraction increased significantly only in group II-V and insignificant in group VI (Fig.10). The percentage changes of the rate of urine flow (Fig.11), urinary osmolar excretion (Fig.12), osmolar clearance (Fig.12) and free water clearance (Fig.13) of animals in group II-VI were greater than the mean value in the same period of control group (group I), while urine osmolality (Fig.11) was shown in the opposite pattern. However, there were no significant changes in



Fig.6:Percentage changes of effective renal plasma flow(ERPF)in dogs infusion with CaCl<sub>2</sub>and pretreated with low(L)or high(H)dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Frazosin[Ver.(H)+Pra.] The values are mean+S.E.

p-values with respect to groupI at the same time interval, p<0.05, p<0.01, p<0.001



Fig.7:percentage changes of effective renal blood flow(ERBF)in dogs infusion with CaCl<sub>2</sub>and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.)and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S.E.

p-values with respect to control condition of each group, p<0.05,
\*\*p<0.01, \*\*\*p<0.001</pre>

p-values with respect to groupI at the same time interval, p<0.01,  $\frac{@@}{p<0.001}$ 



Fig.8:Percentage changes of glomerular filtration rate(GFR) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean<u>+S.E.</u> p-values with respect to control condition of each group, \*p<0.05,</pre>

\*\* p<0.01

p-values with respect to groupI at the same time interval, p<0.05, p<0.01, p<0.001



Fig.9:Percentage changes of renal vascular resistance(RVR) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S.E.

p-values with respect to control condition of each group, p<0.05, \*\*p<0.01, \*\*\*p<0.001</pre>

p-values with respect to groupI at the same time interval, p<0.05,  $\frac{QQ}{p}<0.01$ , p<0.001



Fig.10:Percentage changes of renal fraction(RF) and filtration fraction(FF)
in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H)
dcse cf Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between
high dose of Verapamil and Frazosin[Ver.(H)+Pra.]
The values are mean+S.E.
p-values with respect to control condition of each group, p<0.05,
 \*\*p<0.01
p-values with respect to groupI at the same time interval, p<0.05,
 @@p<0.01, @@@p<0.001</pre>



Fig.11:Percentage changes of urine flow(V)and urine osmolality(U<sub>Csm</sub>)in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S.E.

p-values with respect to control condition of each group, \*p<0.05,
\*\*p<0.01, \*\*p<0.001</pre>

p-values with respect to groupI at the same time interval, p<0.05, p<0.01, p<0.001



Fig.12:Percentage changes of urinary osmolar excretion(U = V) and osmolar Osm clearance(C  $_{\rm Osm}$  ) in dogs infusion with CaCl  $_2$  and pretreated with low(L)or high(H) dose of Verapamil(Ver.), Prazosin(Pra.) and the combined drugs between high dcse of Verapamil and Prazosin[Ver.(H)+ Pra.] . The values are mean+S.E. p-values with respect to control condition of each group, p<0.05, \*\*p<0.01 p-values with respect to groupI at the same time interval, p<0.05, @@p<0.01, @@@p<0.001



Fig.13:Percentage changes of free water clearance(C<sub>H\_0</sub>) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil (Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S.E. p-values with respect to control condition of each group, \*p<0.05, \*\*p<0.01, \*\*\* p<0.001 p-values with respect to groupI at the same time interval, <sup>@</sup>p<0.05, <sup>@@</sup>p<0.01, <sup>@@@</sup>p<0.001</pre>





Fig.14:Percentage changes of plasma osmolality(P\_Osm) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H) dose of Verapamil(Ver.), Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S E.

No significant differences(P<0.05) were noted from the values during control period and during experimental period



Fig.15:Percentage changes of plasma sodium(P<sub>Na</sub>),potassium(P<sub>K</sub>)and chloride
 (P<sub>Cl</sub>) concentration in dogs infusion with CaCl<sub>2</sub> and pretreated with
 low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the
 combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+
 Pra.]. The values are mean+S.E.

No significant differences(p<0.05)were noted from the values during control period and during experimental period



Fig.16:Percentage changes of plasma calcium(P<sub>Ca</sub>) and inorganic phosphorus
(P<sub>Pi</sub>) concentration in dcgs infusion with CaCl<sub>2</sub> and pretreated with
low(L) or high(H) dose of Verapamil(Ver.),Prazosin(Pra.) and the
ccmbined drugs between high dcse of Verapamil and Frazosin[Ver.(H)+
Pra.]. The values are mean+S.E.
p-values with respect to control condition of each group, \*p<0.05,
 \*\*p<0.01, \*\*\*p<0.001
p-values with respect to groupI at the same time interval, p<0.01,
 @@@
p<0.001</pre>

plasma osmolality (Fig.14), plasma concentrations of sodium, potassium and chloride (Fig.15) throughout the experimental period of  $CaCl_2$ infusion. Since the animals given intravenous  $CaCl_2$  infusion, plasma concentration of calcium (Fig.16) elevated persistently all along the study periods. It was observed that plasma concentration of inorganic phosphorus (Fig.16) also increased to the higher level as compared with the control group (group I).

#### Effects of intravenous CaCl<sub>2</sub> infusion on renal electrolytes excretion

#### Group I : Control animals

As shown in table 13, fractional excretion of calcium (FE<sub>Ca</sub>) slightly decreased from  $2.33\pm0.71$  to  $1.88\pm0.66$  % (p(0.05) at the 2<sup>nd</sup> hour period after intravenous isotonic saline infusion. The other variables did not significantly alter thoughout the experimental period.

#### Group II : Hypercalcemic animals

Effects of intravenous  $CaCl_2$  infusion on renal electrolytes excretion are shown in table 14. The  $CaCl_2$  infusion caused a significant increase in fractional excretion of sodium (FE<sub>Na</sub>) and chloride (FE<sub>C1</sub>) at the 1<sup>st</sup> hour period and increased progressively to reach a significant level at the 3<sup>rd</sup> hour period of CaCl<sub>2</sub> infusion (p<0.01 and p<0.05). It has been shown that the similar trend was observed in urinary excretion of sodium (U<sub>Na</sub>V) and chloride (U<sub>C1</sub>V).

Table 13 Effects of intravenous isotonic saline infusion on renal electrolytes excretion in the left kidney of four control dogs. (Mean+S.E.)

|                   | Saline infusion |               |              |               |  |  |  |
|-------------------|-----------------|---------------|--------------|---------------|--|--|--|
| *                 |                 | Sali          | ne infusion  | 5 .           |  |  |  |
| Variables         | Control         | .1 hr.        | 2 hr.        | ·3 hr.        |  |  |  |
| U V<br>Na         | 5.38            | 5.42          | 5.33         | 6.13          |  |  |  |
| (µEg/min/kg.bw.)  | <u>+</u> 0.73   | +0.67         | +0.63        | <u>+</u> 1.03 |  |  |  |
| υ <sub>κ</sub> ν  | 0.85            | 0.74          | 0.74         | 0.99          |  |  |  |
| (uEq/min/kg.bw.)  | <u>+</u> 0.21   | <u>+</u> 0.15 | +0.15        | +0.28         |  |  |  |
| U <sub>Cl</sub> V | 5.79            | 5.86          | 5.47         | 7.15          |  |  |  |
| (µEq/min/kg.bw.)  | <u>+</u> 0.80   | +0.60         | +0.58        | <u>+</u> 0.83 |  |  |  |
| U V<br>Ca         | 0.13            | 0.12          | 0.11         | 0.20          |  |  |  |
| (µEq/min/kg.bw.)  | <u>+</u> 0.05   | <u>+</u> 0.05 | +0.05        | +0.05         |  |  |  |
| U <sub>Pi</sub> V | 0.72            | 0 58          | 0.79         | 1.14          |  |  |  |
| (µEq/min/kg.bw)   | +0.26           | +0.13         | +0.22        | <u>+0.22</u>  |  |  |  |
| FE <sub>Na</sub>  | 2.31            | 2.29          | 2.32         | 2.51          |  |  |  |
| (%)               | +0.30           | +0.22         | +0.26        | +0.35         |  |  |  |
| FEK               | 16.03           | 14.07         | 13.94        | 17.73         |  |  |  |
| (%)               | +3.56           | <u>+</u> 3.52 | +2.73        | <u>+</u> 4.61 |  |  |  |
| FE <sub>C1</sub>  | 2.92            | 2.94          | 2.81         | 3.44          |  |  |  |
| ( % )             | +0.34           | +0.23         | <u>+0.26</u> | <u>+</u> 0.33 |  |  |  |
| FECa              | 2.33            | 2.15          | 1.88         | 2.17          |  |  |  |
| (%)               | <u>+</u> 0.71   | <u>+</u> 0.70 | +0.66        | +0.67         |  |  |  |
| FE <sub>Pi</sub>  | 14.28           | 13.96         | 16.96        | 23.54         |  |  |  |
| ( % )             | +3.42           | +3.10         | +3.81        | +6.54 .       |  |  |  |

P-value with respect to control, \*p<0.05



|                              | Sal           | ine infusion  |                         |                |
|------------------------------|---------------|---------------|-------------------------|----------------|
| ·                            | <b></b>       | After         | CaCl <sub>2</sub> infus | sion           |
| Variables                    | Control       | 1 hr.         | 2 hr.                   | 3 hr.          |
| U V<br>Na                    | 3.31          | 7.13          | 7.68                    | 10.57          |
| (µEq/min/kg.bw.)             | <u>+</u> 1.18 | +1.83         | +1.89                   | <u>+</u> 1.75  |
| υ <sub>κ</sub> ν             | 0.73          | 1.48          | 1.93                    | 2.65           |
| (uEq/min/kg.bw.)             | +0.17         | +0.31         | +0.21                   | +0.20          |
| <sup>U</sup> C1 <sup>V</sup> | 3.65          | 8.87          | 10.67                   | 12.94          |
| (µEq/min/kg.bw.)             | +1.66         | +2.38         | +2.66                   | +2.34          |
| υ <sub>Ca</sub> v            | 0.10          | 0.48          | 0.57                    | 0.67           |
| (µEq/min/kg.bw.)             | +0.02         | +0.11         | +0.08                   | +0.06          |
| U <sub>Pi</sub> V            | 0.72          | 137           | 1.88                    | 2.34           |
| (µEq/min/kg.bw.)             | <u>+0.16</u>  | <u>+</u> 0.27 | <u>+</u> 0.39           | <u>+</u> 0.55  |
| FE Na                        | 1.28          | 3.27          | 4.16                    | 5.28           |
| (%)                          | +0.45         | +0.97         | +1.20                   | +0.81          |
| FEK                          | 13.31         | 28.99         | 41.58                   | 59.39          |
| (%)                          | +3.88         | <u>+8.27</u>  | +4.27                   | +10.86         |
| FE <sub>C1</sub>             | 1.78          | 4.84          | 6.88                    | 8.05           |
| (%)                          | +0.82         | +1.28         | <u>+</u> 1.77           | <u>+</u> 1.39  |
| FE                           | 1.31          | 5.11          | 6.32                    | 7.25           |
| (%)                          | +0.35         | <u>+1.41</u>  | <u>+</u> 1.38           | +1.23          |
| FE<br>Pi                     | 15.13         | 27.81         | 39.04                   | 50.52          |
| (%)                          | +3.00         | +6.71         | <u>+</u> 11.15          | <u>+</u> 13.06 |

Table 14 Effects of intravenous CaCl<sub>2</sub> infusion on renal electrolytes excretion in the left kidney of five dogs. (Mean+S.E.)

P-value with respect to control, p<0.05, \*\* p<0.01, \*\*\* p<0.001

There were marked increases in fractional excretion of potassium (FE<sub>K</sub>) and urinary excretion of potassium (U<sub>K</sub>V) as well as urinary excretion of inorganic phosphorus (U<sub>Pi</sub>V) at the 2<sup>nd</sup> hour and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion (p(0.05). Fractional excretions of both calcium (FE<sub>Ca</sub>) and inorganic phosphorus (FE<sub>Pi</sub>) markedly increased at the 1<sup>st</sup> hour of CaCl<sub>2</sub> infusion and revealed a significant value at the 3<sup>rd</sup> hour (p(0.05) whereas urinary excretion of calcium increased significantly at the 1<sup>st</sup> hour (p(0.05) and progressively increased at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion (p(0.001).

# <u>Group III</u> : Animals pretreated with a low dose of Verapamil (6 µg/kg in the rate of 1 ml/min)

As shown in table 15, it was observed that after intravenous CaCl<sub>2</sub> infusion, fractional excretion of sodium increased continuously and revealed a significant value from 1.47+0.54 to 6.81+1.46 % and to 8.71+1.44 % (p $\langle 0.01 \rangle$ ) at the 2<sup>nd</sup> and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion, respectively. At the same time periods, fractional excretion of chloride also increased in the similar pattern (p(0.001)). There were significant increases in fractional excretion of potassium (p(0.001))and inorganic phosphorus (p(0.01) all the experimental periods. Fractional excretion of calcium increased persistently from 1.51+0.47 to 7.75+1.17 % (p(0.01) and to 9.61+0.80 % (p(0.001) at the 2<sup>nd</sup> and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion, respectively. Both urinary excretion of elevated progressively from 2.72+1.00 sodium to 15.06+1.65 uEq/min/kg.bw. (p(0.001) and chloride from 2.44+0.83 to 17.38+1.16

Table 15 Effects of intravenous CaCl<sub>2</sub> infusion on renal electrolytes excretion in the left kidney of five dogs pretreated with a low dose of Verapamil (6 µg/kg in the rate of 1 ml/min). (Mean+S.E.)

|                              |               | Ver                      | fusion        |               |               |
|------------------------------|---------------|--------------------------|---------------|---------------|---------------|
|                              |               | Before CaCl <sub>2</sub> | After Ca      | Cl_ infusio   | on            |
| Variables                    | Control       | infusion                 | 1 hr.         | 2 hr.         | 3 hr.         |
| U V<br>Na                    | 2.72          | 3.48                     | 7.18          | 12.09         | 15.06         |
| (uEq/min/kg.bw.)             | <u>+</u> 1.00 | +0.81                    | +2.21         | +2.33         | <u>+</u> 1.65 |
| υ <sub>κ</sub> ν             | 0.82          | 0.71                     | 1.47          | 2.19          | ***<br>2.40   |
| (µEq/min/kg.bw.)             | +0.11         | +0.04                    | +0.16         | +0.08         | +0.12         |
| <sup>U</sup> C1 <sup>V</sup> | 2.44          | 3.39                     | 8.19          | 13.66         | 17.38         |
| (µEq/min/kg.bw.)             | +0.83         | <u>+</u> 0.95            | +2.31         | <u>+</u> 1.84 | <u>+</u> 1.16 |
| υ <sub>Ca</sub> v            | 0.08          | 0.08                     | 0.35          | 0. 62         | ***<br>079    |
| (µEq/min/kg.bw.)             | +0.03         | +0.02                    | +0.10         | +0.09         | <u>+</u> 0.04 |
| U <sub>Pi</sub> V            | 0.67          | 0.61                     | 090           | .231          | ***<br>2. 70  |
| (µEq/min/kg.bw.)             | +0.08         | +0.08                    | +0.28         | +024          | +0.22         |
| FE <sub>Na</sub>             | 1.47          | 1.79                     | 3.98          | 6.81          | 8.71          |
| (%)                          | +0.54         | +0.14                    | +1.39         | +1.46         | +1.44         |
| FEK                          | 19.95         | 15.70                    | 36.18         | 57.02         | 63.62         |
| (%)                          | +4.12         | +2.35                    | +5.77         | +5.00         | +7.54         |
| FE <sub>C1</sub>             | 2.04          | 2.38                     | 5.88          | 9.61          | 12.37         |
| (%)                          | +0.75         | +0.72                    | <u>+</u> 1.98 | +1.65         | +1.65         |
| FE                           | 1.51          | 1.50                     | 4.37          | 7.75          | 9.61          |
| (%)                          | +0.47         | +0.35                    | <u>+</u> 1.31 | +1.17         | +0.80         |
| FEpi                         | 19.79         | 16.52                    | 30.96         | 49.15         | 56.72         |
| (%)                          | <u>+4.57</u>  | +2.10                    | +3.57         | +1.59         | +2.56         |
|                              |               |                          |               |               |               |

P-value with respect to control, p<0.05, \*\* p<0.01, \*\*\* p<0.001

 $\mu$ Eq/min/kg.bw. (p(0.001) at the end of the experiment. Urinary excretion of potassium, calcium and inorganic phosphorus also significant increased progressively all the experimental periods (p(0.001).

# <u>Group IV</u> : Animals pretreated with a high dose of Verapamil (12 µg/kg in the rate of 1 ml/min)

The results are shown in table 16. A significant increase in fractional excretion of sodium was observed gradually from 1.60+0.25 to 8.51+1.61 % (p(0.05) and to 9.10+1.77 % (p(0.05) at the 2<sup>nd</sup> and 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion, respectively; whereas fractional excretion of chloride marked increased in all the experimental periods (p(0.01)). It was found that fractional excretion of potassium elevated progressively from 14.71+2.92 to 57.64+4.75 % (p(0.01) at the 3<sup>rd</sup> hour of CaCl<sub>2</sub> infusion. Fractional excretion of calcium as well as inorganic control value and reached the phosphorus increased from the significant level at the  $2^{nd}$  (p(0.01) and  $3^{rd}$  hour of CaCl<sub>2</sub> infusion (p(0.01, p(0.05)). It was indicated that urinary excretion of sodium, potassium and chloride increased significantly as the same pattern of Either urinary excretion of calcium or its fractional excretion. inorganic phosphorus showed a significant incrase all the experimental periods.

Table 16 Effects of intravenous CaCl<sub>2</sub> infusion on renal electrolytes excretion in the left kidney of five dogs pretreated with a high dose of Verapamil (12,ug/kg in the rate of 1 ml/min). (Mean+S.E.)

|                   |               | Verapamil infusion       |               |               |                 |  |
|-------------------|---------------|--------------------------|---------------|---------------|-----------------|--|
|                   | ·             | Before CaCl <sub>2</sub> | After C       | aCl_ infusi   | on              |  |
| Variables         | Control       | infusion                 | 1 hr.         | 2 hr.         | 3 hr.           |  |
| U V<br>Na         | . 3.23        | 5.39                     | 11.12         | 15.48         | 15.81           |  |
| (µEq/min/kg.bw.)  | +0.54         | <u>+</u> 1.57            | +2.89         | +2.73         | <u>+</u> 2.92   |  |
| υ <sub>κ</sub> ν  | 0.65          | 0.93                     | 1.85          | 2.27          | 2.33            |  |
| (µEq/min/kg.bw.)  | +0.10         | +0.18                    | +0.22         | +0.23         | +0.27           |  |
| U <sub>C1</sub> V | 3.13          | 4.81                     | 13.11         | 18.38         | 19.55           |  |
| (µEq/min/kg.bw.)  | +0.67         | <u>+</u> 1.68            | +2.99         | +2.86         | <u>+</u> 3.01   |  |
| U <sub>Ca</sub> V | 0.10          | 0.11                     | 0.56          | 0. 81         | **<br>0- 88     |  |
| (µEq/min/kg.bw.)  | +0.02         | +0.04                    | +0.14         | <u>+</u> 0.37 | <u>+</u> 0.16   |  |
| u <sub>pi</sub> v | 0.73          | 0.84                     | 1.39          | 2. 02         | 2- 21           |  |
| (µEq/min/kg.bw.)  | +0.14         | <u>+</u> 0.13            | +0.06         | <u>+</u> 0.12 | <u>+</u> 0 - 22 |  |
| FE Na             | 1.60          | 2.45                     | 6.13          | 8.51          | 9.10            |  |
| (%)               | +0.25         | <u>+</u> 0.71            | +1.69         | <u>+</u> 1.61 | <u>+</u> 1.77   |  |
| FE <sub>K</sub>   | 14.71         | 19.05                    | 43.96         | 54.27         | 57.64           |  |
| (%)               | <u>+</u> 2.92 | +2.75                    | <u>+</u> 4.83 | +5.24         | <u>+</u> 4,75   |  |
| <sup>FE</sup> C1  | 1.86          | 2.63                     | 8.64          | 11.99         | 13.46           |  |
| (%)               | +0.39         | +0.92                    | +2.19         | +2.18         | +2.21           |  |
| FE                | 2.42          | .1.79                    | 6,72          | 9.40          | 10.44           |  |
| (%)               | +0.86         | <u>+</u> 0_61            | <u>+</u> 1.77 | +1.46         | <u>+</u> 1.84   |  |
| FE                | 21.10         | 21.69                    | 22.16         | 43.92         | 52.69           |  |
| (%)               | +4.75         | +3.48                    | +2.01         | +1.69         | <u>+</u> 1.39   |  |
|                   |               |                          |               |               |                 |  |

P-value with respect to control, p<0.05, \*\* p<0.01



<u>Group V</u> : Animals pretreated with Prazosin (20 مر kg in the rate of 1 ml/min)

As shown in table 17. Fractional excretion of sodium increased from  $1.66\pm0.45$  to  $9.17\pm2.92$  % (p(0.05) and chloride from  $1.72\pm0.49$  to  $12.57\pm3.56$  % (p(0.05) after 3 hour of CaCl<sub>2</sub> infusion. A marked increase in fractional excretion of potassium was noted significantly all the experimental periods (p(0.01). It was observed that, both fractional excretion of calcium and inorganic phosphorus increased gradually in the same pattern at  $1^{\text{st}}$ ,  $2^{\text{nd}}$  and  $3^{\text{rd}}$  hour of CaCl<sub>2</sub> infusion (p(0.05). Urinary excretion of sodium, potassium, chloride and inorganic phosphorus were elevated significantly as the same pattern of its fractional excretion at all periods.

# <u>Group VI</u>: Animals pretreated with the combination both of high dose of Verapamil and Prazosin

The results are summarized in table 18. The CaCl<sub>2</sub> infusion caused a significant increase in fractional excretion of sodium from  $2.37\pm0.55$  to  $5.69\pm0.50$  % (p(0.001) and chloride from  $2.54\pm0.66$  to  $8.72\pm0.62$  % (p(0.01) at the end of CaCl<sub>2</sub> infusion. Fractional excretion of calcium was also increased progressively which correlated with its urinary excretion (p(0.01). Both urinary excretion of sodium and chloride elevated significantly in the same pattern of its fractional excretion at all periods (p(0.001 and p(0.01). There was indicated that, urinary excretion of potassium increased slightly at the 2<sup>nd</sup> hour

Prazosin infusion Eefore CaCl, After CaCl, infusion Variables Control infusion 1 hr. 2 hr. 3 hr. 8.71 13.56 14.54 UNAV 3.10 5.19 (µEq/min/kg.bw.) +0.87 +1.56 +2.05 +2.71 +3.77 2.27 UKV 1.52 2.24 0.60 0.71 (µEq/min/kg.bw.) +0.28 +0.09 +0.14 +0.12 +0.08 U<sub>C1</sub>V 10.36 16.31 17.43 2.78 4.78 ()Eq/min/kg.bw.) +2.18 +0.77 +1.61 +2.87 +4.02 0.59 0.72 0-84 UCaV 0.09 0.17 (uEq/min/kg.bw.) +0.03 +0.06 +0.16 +0.12 +0.18 1. 65 2.13 2.23 0,68 U<sub>Pi</sub>V 1.06 (µEq/min/kg.bw.) +0.14+0.20 +0.18 +0.38 +0.11 8.01 9.17 FE<sub>Na</sub> 5.10 1.66 2.51 (%) +0.45 +0.69 +1.33 +2.07 +2.92 57.38 37.30 59.57 FEK 13.19 14.44 (%) +1.64 +1.05 +3.96 +5.35 +10.64 6.94 12.57 FE cl 11.15 1.72 2.81 (%) +0.49 +0.87 +2.61 +1.55 +3.56 <sup>FE</sup>Ca 8.13 9.39 11.36 1.99 3.34 (%) +0.56 +2.74 +1\_19 +2.45 +1.89 37.84 FE<sub>Pi</sub> 49.55 55.45 19.44 25.14 (%) +3.11+4.05 +6.31 +4.32 +9.48

Table 17Effects of intravenous CaCl2 infusion on renal electrolytesexcretion in the left kidney of five dogs pretreated withPrazosin (20 µg/kg in the rate of 1 ml/min).(Mean+S.E.)

P-value with respect to control, p<0.05, \*\* p<0.01, \*\* p<0.001

Table 18 Effects of intravenous CaCl<sub>2</sub> infusion on renal electrolytes excretion in the left kidney of five dogs pretreated with the combination of high dose of Verapamil and Prazosin (Mean+S.E.)

| ÷                 |               | Verapamil+Prazosin infusion |                         |                 |               |  |
|-------------------|---------------|-----------------------------|-------------------------|-----------------|---------------|--|
|                   |               | Before CaCl <sub>2</sub>    | After CaCl <sub>2</sub> | infusion        |               |  |
| Variables         | Ccntrol       | infusion                    | 1 hr.                   | 2 hr.           | 3 hr.         |  |
| U V               | 4.95          | 5.82                        | 13.43                   | 15.84           | 13.75         |  |
| (µEq/min/kg.bw.)  | <u>+</u> 0.83 | <u>+</u> 1.03               | +0.77                   | <u>+</u> 1.59   | <u>+</u> 1.06 |  |
| υ <sub>κ</sub> ν  | 0.50          | 0.66                        | 1.20                    | 1.56            | 1.82          |  |
| (µEq/min/kg.bw.)  | +0.14         | <u>+</u> 0.08               | <u>+</u> 0.18           | <u>+</u> 0.16   | <u>+</u> 0.18 |  |
| U <sub>C1</sub> V | 4.38          | 5.51                        | 15.26                   | 18.17           | 17.14         |  |
| (µEq/min/kg.bw.)  | +0.99         | <u>+</u> 0.76               | +0.73                   | <u>+</u> 1_88   | <u>+</u> 1.34 |  |
| υ <sub>ca</sub> v | 0.10          | 0.13                        | 0.82                    | .1. 02          | °97           |  |
| (µEq/min/kg.bw.)  | +0.02         | +0.03                       | +0.10                   | <u>+</u> 0 - 15 | <u>+</u> 0.17 |  |
| U <sub>pi</sub> v | 0.84          | 0.78                        | 1.56                    | 2.04            | ***<br>2•49   |  |
| (µEq/min/kg.bw.)  | +0.28         | +0.31                       | +0.27                   | <u>+</u> 0.38   | +0.17         |  |
| FENS              | 2.37          | 2.52                        | 5.16                    | 6.45            | 5.69          |  |
| (%) -             | +0.55         | +0.53                       | +0.34                   | +0.65           | <u>+</u> 0.50 |  |
| FE                | 11.23         | 13.23                       | 20.39                   | 26.42           | 30.66         |  |
| (%)               | <u>+</u> 4.31 | +2.75                       | +1.81                   | +3.16           | +5.02         |  |
| FE <sub>CI</sub>  | 2.54          | 2.98                        | 7.63                    | 9.07            | 8.72          |  |
| (%)               | <u>+</u> 0.66 | +0.62                       | +0.66                   | +0.95           | +0.62         |  |
| FE                | 1.99          | 2.28                        | 8.37                    | 10.39           | 9.58          |  |
| (%)               | <u>+</u> 0.58 | +0.53                       | +1.04                   | <u>+</u> 1.74   | <u>+</u> 1.96 |  |
| FE                | 22.17         | 18.15                       | 29.17                   | 36.20           | 46.81         |  |
| (%)               | +6.41         | <u>+</u> 6.67               | +5.23                   | <u>+</u> 6.93   | +5.63         |  |

P-value with respect to control, \*p<0.05, \*\*p<0.01, \*\*\*</pre>

 $(p \langle 0.01 \rangle)$  and  $3^{rd}$  hour of CaCl<sub>2</sub> infusion  $(p \langle 0.05 \rangle)$ , whereas fractional excretion of potassium increased significantly only at the  $3^{rd}$  hour of CaCl<sub>2</sub> infusion  $(p \langle 0.05 \rangle)$ . Fractional excretion of inorganic phosphorus increased slightly and reached a significant level at the  $2^{nd}$  and  $3^{rd}$  hour of CaCl<sub>2</sub> infusion  $(p \langle 0.01 \rangle)$ , while its urinary excretion increased significantly at all periods.

In comparison of the results, three hour after intravenous CaCl<sub>2</sub> infusion, fractional excretion of sodium (Fig.17), potassium (Fig.18), chloride (Fig.19), calcium (Fig.20) and inorganic phosphorus (Fig.21) were increased significantly all experimental periods in group II-VI as compared to the control group (group I) at interval. It indicated that, the same time was urinary excretion of sodium (Fig.22), potassium (Fig.23), chloride (Fig.24), calcium (Fig.25) and inorganic phosphorus (Fig.26) of animals in group II-VI markedly increased in the similar pattern which significantly differed from the control group (group I) throughout the experimental It has been shown that alterations of percentages of periods. fractional excretion of sodium (Fig.17) and chloride (Fig.19) of animals in group VI were less than that of group II-V throughout the study period. Similar changes were noted in urinary excretion of sodium (Fig.22) and chloride (Fig.24) in the same time interval.



Fig.17: Percentage changes of fractional excretion of sodium(FE<sub>Na</sub>)
in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or
high(H)dose of Verapamil(Ver.),Prazosin(Pra.)and the combined
drugs between high dose of Verapamil and Prazosin[Ver.(H)+
Pra.]. The values are mean+S.E.
p-values with respect to control condition of each group, \*p<0.05
\*\*p<0.01, \*\*\*p<0.001</pre>

p-values with respect to group I at the same time interval,  ${}^{@}_{p<0.05}, {}^{@}_{p<0.01}, {}^{@}_{p<0.001}$ 



Fig.18: Percentage changes of fractional excretion of potassium(FE<sub>K</sub>)
in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or
high(H)dose of Verapamil(Ver.),Prazosin(Pra.)and the combined
drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.]
The values are mean+S.E.

p-values with respect to control condition of each group, \*p<0.05,\*\*p<0.01,\*\*\*p<0.001</pre>

p-values with respect to group I at the same time interval, p < 0.05, p < 0.01, p < 0.001





p-values with respect to control condition of each group, \*p<0.05, \*\*p<0.01, \*\*\* p<0.001</pre>

p-values with respect to group I at the same time interval,  $^{0}_{p<0.05}$ ,  $^{00}_{p<0.01}$ ,  $^{000}_{p<0.001}$ 

78





p-values with respect to control condition of each group, \*p<0.05,\*\*p<0.01,\*\*\* p<0.001</pre>

p-values with respect to group I at the same time interval, p<0.05, p<0.01, p<0.001



80



Fig.21: Percentage changes of fractional excretion of inorganic
 phosphorus(FE<sub>Pi</sub>)in dogs infusion with CaCl<sub>2</sub> and pretreated
 with low (L)or high(H)dose of Verapamil(Ver.),Prazosin(Pra.)
 and the combined drugs between high dose of Verapamil and
 Prazosin[Ver.(H)+Pra.]

The values are mean+S.E.

p-values with respect to control condition of each group, \*p<0.05, \*\*p<0.01

p-values with respect to group I at the same time interval, p<0.05, p<0.01, p<0.001



Fig. 22: Percentage changes of urinary excretion of sodium(U<sub>Na</sub>V)in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L)or high(H)dose of Verapamil(Ver.),Prazosin(Pra.)and the combined drugs between high dose of Verapamil and Prazosin[Ver.(H)+Pra.] The values are mean+S.E. p-values with respect to control condition of each group, \*p<0.05, \*p<0.01, \*\*\*p<0.001 p-values with respect to group I at the same time interval,

p-values with respect to group I at the same time interval  $\substack{0\\p<0.05, p<0.01, p<0.001}$ 



Fig.23:Percentage changes of urinary excretion of potassium(U<sub>K</sub>V) in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H)dose of Verapamil(Ver.),Prazosin(Pra.) and the combined drugs between high dose of Verapamil and Frazosin[Ver.(H)+Pra.] The values are mean+S.E.

p-values with respect to control condition of each group, \*p<0.05,
\*\*p<0.01, \*\*\*p<0.001</pre>

p-values with respect to groupI at the same time interval, p<0.05, p<0.01, p<0.001



Fig. 24: Percentage changes of urinary excretion of chloride(U<sub>Cl</sub>V)
in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L)or
high(H)dose of Verapamil(Ver.),PRazosin(Pra.)and the combined
drugs between high dose of Verapamil and Prazosin[Ver.(H)+
Pra.]
The values are mean+S.E.

p-values with respect to control condition of each group, p<0.05, p<0.01, p<0.001

p-values with respect to group I at the same time interval,  $p^{(0)} > 0.05$ ,  $p^{(0)} > 0.01$ ,  $p^{(0)} > 0.001$ 







Fig. 26: Percentage changes of urinary excretion of inorganic phosphorus

(U<sub>Pi</sub>V)in dogs infusion with CaCl<sub>2</sub> and pretreated with low(L) or high(H)dose of Verapamil(Ver.),Prazosin(Pra.)and the combined drugs between high dose of Verapamil and Prazosin [Ver.(H)+Pra.]

The values are mean+S.E.

p-values with respect to control condition of each group, \*p<0.05.\*\*p<0.01,\*\*\*p<0.001</pre>

p-values with respect to group I at the same time interval, p<0.05, p<0.01, p<0.001